Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
Study shows efficacy of biologics for mucosal healing in Crohn's disease and ulcerative colitis

Study shows efficacy of biologics for mucosal healing in Crohn's disease and ulcerative colitis

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

Patients with noninfectious uveitis can get effective treatment from corticosteroid alternative

Patients with noninfectious uveitis can get effective treatment from corticosteroid alternative

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Guselkumab drug more effective than current standard of care for psoriasis

Guselkumab drug more effective than current standard of care for psoriasis

Study: New test may help predict effectiveness of biologic drugs in RA patients

Study: New test may help predict effectiveness of biologic drugs in RA patients

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints